Androgen deprivation, a consequence of hypogonadism, certain cancer treatments, or normal aging in men, leads to loss of muscle mass, increased adiposity, and osteoporosis. In the present study, using a soluble chimeric form of activin receptor type IIB (ActRIIB) we sought to offset the adverse effects of androgen deprivation on muscle, adipose tissue, and bone. . These changes were also accompanied by altered serum levels of leptin, adiponectin, and insulin, as well as by prevention of steatosis (fatty liver) in ActRIIB-mFc-treated ORX mice. Finally, ActRIIB-mFc prevented loss of bone mass in ORX mice as assessed by whole body dual x-ray absorptiometry and micro-computed tomography of proximal tibias. The data demonstrate that treatment with ActRIIB-mFc restored muscle mass, adiposity, and bone quality to normal levels in a mouse model of androgen deprivation, thereby alleviating multiple adverse consequences of such therapy. (Endocrinology 151: 4289 -4300, 2010) 
A ndrogens, such as testosterone in men, regulate lean tissue mass, adipose tissue mass, and bone turnover. Low androgen levels result from congenital conditions, such as hypogonadism, but are also a consequence of normal aging in men, where serum testosterone levels have been shown to decline by 10% during each decade after the age of thirty (1, 2) . This age-related decline in testosterone has been implicated as a contributing factor in agerelated loss of muscle mass, increase in central (abdominal) adiposity, and development of osteoporosis (3) . Furthermore, lowering androgen levels is a therapeutic goal of androgen-deprivation therapies used in patients with androgen-dependent cancers, such as prostate, bladder, and mammary cancers. Unfortunately, this lifeprolonging treatment is accompanied by the adverse sideeffects of androgen deprivation resulting in increased adiposity, loss of muscle mass, and osteoporosis.
Prostate cancer is the most commonly diagnosed noncutaneous cancer in U.S. men, accounting for nearly 200,000 new cases annually (4) . Due to the importance of androgens in the growth of prostate cancer cells, androgen deprivation therapy is considered first-line treatment for advanced (metastatic) prostate cancer and is also used as adjunct therapy for men receiving radiation for high-risk localized (nonmetastatic) disease (5) . Androgen deprivation, which consists of irreversible surgical orchiectomy (ORX) or reversible pharmacologic treatment ("medical castration"), improves survival but can lead to a spectrum of effects that negatively impact quality of life. Prominent among these are: 1) fatigue with decreased muscle mass; 2) osteoporosis with increased risk of fracture; and 3) metabolic alterations with increased adiposity and increased risk of insulin resistance, diabetes, and cardiovascular disease (5) (6) (7) . Compounding the problem, detrimental changes in these end points often occur with aging even before the commencement of androgen deprivation (8) . Thus, there is a need for strategies to reduce the severity of such effects and to improve the quality of life for prostate cancer patients treated with androgen deprivation therapy.
Multiple growth and differentiation factor (GDF) family members, including myostatin (GDF-8), signal through activin receptor type IIB (ActRIIB). These factors have been shown to regulate muscle mass and may also be involved in the regulation of bone quality and adipose mass. Previous research in rodents has demonstrated that inhibition of ActRIIB signaling with a chimeric ActRIIB derivative (ActRIIB-mFc), consisting of the extracellular domain of human ActRIIB fused to a murine IgG2a Fc domain, results in greatly increased muscle mass in healthy mice (9, 10) and mice with amyotrophic lateral sclerosis (11) . GDF-11 is another member of the TGF-␤ family that signals through ActRIIB and is of similar structure to GDF-8. Role of GDF-11 has been implicated in regulation of bone formation throughout development, but until recently GDF-8 has only been associated with muscle tissue growth and maintenance. However, a recent study demonstrated that both GDF-11 and GDF-8 are involved in regulation of skeletal development and may have redundant functions (12) . Concerning the regulation of adipose mass, myostatin-deficient mice have increased muscle mass, accumulate less fat throughout life than wildtype control animals, and display resistance to dietinduced obesity (13) . This effect of myostatin on fat mass is presumably due to increased muscle mass of myostatindeficient mice.
Castration/orchiectomy (ORX) in mice produces changes in body composition similar to those in men undergoing androgen deprivation therapy, including reduced weight gain, reduced muscle mass, loss of bone with elevated turnover, and increased fat mass (14 -16) . Therefore, we used an ORX mouse model of androgen deprivation to investigate the effects of ActRIIB-mFc on muscle mass, bone quality, adiposity, and adiposity-related systemic physiological changes, such as circulating concentrations of adipocyte-derived endocrine factors (adipokines) and accumulation of triglycerides in liver tissue. ACE-031 is the human version of ActRIIB-mFc and is currently in Phase I clinical study in human volunteers, where preliminary results demonstrate that the single dose of ACE-031 increased lean body mass and muscle volume.
Materials and Methods
Construction, expression, and purification of ActRIIB-mIgG2aFc (ActRIIB-mFc)
The ActRIIB extracellular domain (Ser 19 -Thr 134 ) was obtained by PCR amplification. The purified PCR fragment and the pAIDT4 mIgG2a vector were ligated to create the expression construct, and the sequence was confirmed by double-stranded dideoxy sequencing. The pAIDT4-ActRIIB-mIgG2a construct was transiently transfected into HEK293 cells. After 1 wk of growth at 37 C, the conditioned media were harvested with a two-step column chromatography procedure. The purified ActRIIB-mFc (also termed RAP-031) was eluted from the column and then dialyzed into PBS.
Animals and experimental design
Forty male C57/BL6 mice were randomly assigned to either sham-operated (SHAM) or castrated (ORX) experimental groups at 9 wk of age by Taconic Laboratories (Hudson, NY). The ORX and SHAM animals were allowed to recover for 7 d postsurgery at Taconic and then shipped to our site and allowed to acclimate for another 7 d. All procedures were reviewed and approved by Acceleron Pharma, Inc. Animal Care and Use Committee (IACUC), and all animals were housed in conventional cages with free access to food (regular chow) and water. Before any experimental procedures, all of the metal wound clips were removed and the animals were assessed for proper wound healing. The SHAM and ORX animals were then assigned to either a vehicle-treated group (VEH) or ActRIIB-mFc-treated group (ActRIIB-mFc) and received bi-weekly systemic intraperitoneal administration of TBS or ActRIIB-mFc (10 mg/kg) for 71 d. The ActRIIB-mFc concentration (10 mg/kg) and bi-weekly administration regimen were chosen based on in-house dose-response studies demonstrating maximal efficacy observed with the 10 mg/kg dose on lean tissue mass and pharmacokinetic studies performed in mice, respectively.
Body and terminal tissue weights
Body weights were measured twice per week using an electronic scale at the time of intraperitoneal administration of TBS or ActRIIB-mFc. At study termination date, tissues of interest (muscles, fat depots, and tibias) were surgically removed, weighed using an electronic scale, and properly stored for further analysis. At this time, the ORX animals were also examined to confirm complete removal of testes.
DEXA
Whole body bone composition was analyzed in vivo by dualenergy x-ray absorptiometry (DEXA) with a Lunar PIXImus densitometer (GE Medical Systems, Fitchburg, WI) using a high-resolution digital picture (0.18 ϫ 0.18 pixels, resolution of 1.6 line pairs per millimeter) and software version 2.10. The animals were anesthetized using isoflurane and scanned at study d 0 (before administration of ActRIIB-mFc), and then at d 28, 47, and 71 after treatment initiation. The manufacturer reports the image pixel size of 0.035 mm 2 where the total x-ray absorbance threshold for bone per pixel is applied automatically by the software. To evaluate experimental intrameasurement variability, we performed 10 consecutive scans of three different OVX mice and three SHAM mice. The average (mean) coefficients of variation (% CV) for bone mineral density were 1.37 for the OVX mice and 1.31 for the SHAM mice.
Nuclear magnetic resonance (NMR)
Body composition was analyzed at d 0 (before administration of ActRIIB-mFc), and then at d 14, 28, 47, and 71 after treatment initiation using the MiniSpec LF90 NMR Analyzer (Bruker, Woodlands, TX). The manufacturer reports the theoretical limit of detection/precision as Ϯ0.1 g. To evaluate intrameasurement variability, we performed 10 consecutive scans of three different OVX mice and three SHAM mice. The average (mean) coefficients of variation (% CV) for lean tissue mass were 1.24 and 3.53 for the OVX and SHAM mice, respectively. The average (mean) coefficients of variation (% CV) for fat tissue mass were 0.72 and 3.6 for the OVX and SHAM mice, respectively.
Ex vivo assessment of bone structure by micro-computed tomography (CT)
Cortical morphometry and trabecular structure of the tibia were evaluated after the experiment termination using a vivaCT 75 small-angle-cone-beam CT imaging system (Scanco Medical AG, Bassersdorf, Switzerland) with resolution of 20.5-156 m nominal (pixel size). Transverse CT slices (729) of tibia, starting from the distal end of proximal tibia metaphysis, were acquired using 20.5-m isotropic voxel size (55 kVp, 145 A, 2048 samples at 1000 projections per 360°, 350 msec integration time). Images were reconstructed, filtered, and a specimen-specific threshold was applied. The tissue density thresholds of detection were obtained through a combination of the manufacturer's presets and visual inspection. These thresholds were kept constant for all of the evaluated specimens. Trabecular structures were quantified using the first 50 slices distal to the growth plate. Cortical bone parameters were evaluated using 50 slices located 400 slices distal to the growth plate. Trabecular morphometric parameters were computed using a direct three-dimensional approach. Bone volume/total volume fraction (BV/TV, %), trabecular thickness (TbTh, m), trabecular separation (TbSp, m), and trabecular number (TbN, mm Ϫ1 ) were assessed. Cortical morphometric parameters were also computed using a direct three-dimensional approach. Bone area (BA, mm 2 ), cortical thickness (C.Th, mm), endosteal perimeter (E.pm, mm), and periosteal perimeter (P.pm, mm) were assessed. To evaluate intrasample variability, we performed 10 consecutive scans of three different bone samples from OVX mice treated with TBS, OVX mice treated with ActRIIB-mFc, and SHAM mice treated with ActRIIB. The average (mean) coefficients of variation (% CV) for the trabecular bone parameters were as follows for OVXϩTBS, OVXϩActRIIB-mFc, and SHAMϩActRIIB-mFc groups: 1.37, 0.98, and 1.73 for bone volume fraction; 1.47, 0.64, and 2.17 for trabecular number; 0.75, 0.98, and 0.88 for trabecular thickness; 1.96, 0.96, and 2.67 for trabecular separation, respectively. The average (mean) coefficients of variation (% CV) for the cortical bone parameters were all less than 1%.
In vivo assessment of abdominal adipose tissue content by CT
Abdominal adiposity was evaluated in anesthetized animals by using the CT system described above. Approximately 450 -500 transverse CT slices starting from T13 thoracic vertebrae and ending at L5 lumbar vertebrae were acquired by using 41-m isotropic voxel size (45 kVp, 177 A, 1024 samples at 1000 projections per 360°, 350 ms integration time). Images were reconstructed, filtered, and a threshold segmenting adipose from other tissue was applied. The tissue density thresholds of detection were obtained through a combination of the manufacturer's presets and visual inspection. These thresholds were kept constant for all of the evaluated specimens. To evaluate intrasample variability, we performed 10 consecutive abdominal scans of three different OVX and SHAM mice treated with TBS. The average (mean) coefficients of variation (% CV) for OVX and SHAM groups were as follows: 2.2 and 1.5 for visceral adiposity, and 1.8 and 4.5 for subcutaneous adiposity, respectively.
In vivo assessment of thigh muscle and adipose tissue content by CT
Tissue composition of a mid-thigh was evaluated in anesthetized animals by using the micro-computed tomography system described above. Transverse CT slices starting from upper thigh (femoral head) down to middle region of patellar tendon were acquired by using 41-m isotropic voxel size (45 kVp, 177 A, 1024 samples at 1000 projections per 360°, 350 msec integration time). Images were reconstructed, filtered, and a threshold segmenting adipose from muscle and other tissue was applied.
Serum analysis
Upon study termination, the animals were euthanized using CO 2 and blood was collected into serum separation tubes. After 10-min centrifugation at 10,000 ϫ g, serum was collected and used for subsequent immunoassays according to manufacturer instructions. Total adiponectin ELISA was purchased from Panomics (Fremont, CA), and the manufacturer reported the minimum detectable limit as 15.6 pg/ml and the assay linear range was 5 g/ml to 320 g/ml. The manufacturer also reported intrameasurement and intermeasurement reproducibility with coefficients of variation (% CV) of less than 10% for the mouse assay. Leptin ELISA was purchased from Crystal Chem (Downers Grove, IL). The reported detection range was from 0.2 to 12.8 ng/ml and intraassay as well as interassay % CVs were less than 10%. Insulin ELISA was purchased from Linco Research (St. Charles, MO). The manufacturer reported a linear detection range from 0.2 ng/ml to 10 ng/ml with mean intraassay and interassay % CV of less than 10%. Orchiectomy was confirmed by measuring extracted serum testosterone levels as detected by RIA [Ligand Assay and Analysis Core, University of Virginia Center for Research in Reproduction, supported by Eunice Kennedy Shriver National Institute of Child Health and Human Development/National Institutes of Health Specialized Cooperative Centers Program in Reproduction and Infertility Research (SCCPIR) Grant U54-HD28934]. For the testosterone assay the reportable range was from 14.8 ng/dl to 776.2 ng/dl, and inter-measurement % CV was less than 10%. For all of the serum assays, the samples reading above the upper limit of detection were diluted and read again.
Histology
Upon study termination, adipose tissue depots and livers were surgically dissected and processed as follows. Adipose tissue depots were fixed overnight in 10% formalin and stored in 70% ethanol. The fixed adipose depots were then paraffin-embedded, sectioned into 10-m sections, and processed for hematoxylin and eosin stain (H&E). Dissected livers were snap frozen in liquid nitrogen, sectioned into 10-m sections, and processed for Oil Red O stain. All images of the stained sections were taken using a camera connected to a light microscope.
Data analysis
Comparisons between treatment groups over time (longitudinal) were made using ANOVA followed by LS Means Differences Tukey HSD post hoc analysis. Comparisons between groups at a single time point (cross) were made using one-way ANOVA Tukey HSD pair test. Differences were considered statistically significant when the two-tailed P value was Յ0.05. All data were analyzed with JMP 8.0 (The SAS Institute, Inc., Cary, NC). Data shown are means Ϯ SEM.
Results
ActRIIB-mFc increases total body mass, total lean tissue mass, and individual muscle mass in SHAM and ORX mice
We investigated effects of ActRIIB-mFc in the orchiectomized (ORX) mouse, an animal model which mimics many of the changes in body composition associated with androgen deprivation therapy. As shown in Fig. 1A , ActRIIB-mFc increased the rate of body mass gain under ORX conditions as well as SHAM conditions relative to treatment with vehicle. By d 71, ORX mice weighed less (28.7 Ϯ 0.75 g) than SHAM mice (30.1 Ϯ 0.64 g, P Ͻ 0.05), while ActRIIB-mFc increased body weights of both ORX (31.7 Ϯ 0.54 g, P Ͻ 0.0001) and SHAM (34.8 Ϯ 0.59 g, P Ͻ 0.0001) animals (Table 1 and Fig. 1A ). This effect was due to a pronounced increase in lean body mass (Fig. 1B) . Whereas ORX controls showed a slight decline in lean body mass (15.6 Ϯ 0.26 g) during the course of treatment, ORX mice treated with ActRIIB-mFc displayed a marked increase in lean body mass (19.8 Ϯ 0.26 g), attaining a mean value 25% significantly higher (P Ͻ 0.0001) than ORX control mice by study completion (Table 1 and Fig.  1B) . A similar significant increase in lean body mass was observed under SHAM conditions for ActRIIB-mFc (23.4 Ϯ 0.35 g) compared with vehicle (19.0 Ϯ 0.42 g, P Ͻ 0.0001). The effects of ORX and ActRIIB-mFc on lean body mass were similar to the above also when lean body mass was expressed as a percentage of the total body mass ( Table 1) . Representative images of a mid-thigh region obtained by micro-computed tomography (micro-CT) illustrate the similarity of body composition in ORX mice treated with ActRIIB-mFc to that in SHAM controls (Fig.  1C) . This increased lean body mass was due to a stimulatory effect of ActRIIB-mFc on muscle mass under both ORX conditions and SHAM conditions. ActRIIB-mFc increased muscle masses of pectoralis major (pectoralis) by 68% (P Ͻ 0.0001) and 53% (P Ͻ 0.001), rectus femoris (femoris) by 54% (P Ͻ 0.0001) and 37% (P Ͻ 0.0001), and gastrocnemius muscles by 51% (P Ͻ 0.0001) and 47% (P Ͻ 0.0001), in both SHAM and ORX mice, respectively (Table 1 and Fig. 1D ). ORX mice had smaller pectoralis major (191.27 Ϯ 12.01 g) and biceps femoris muscles (156.76 Ϯ 5.71 g) than SHAM mice (241.21 Ϯ 9.97 g and 186.69 Ϯ 4.20 g, respectively); however, these changes were not significant (P ϭ 0.087 and P ϭ 0.089, respectively). Gastrocnemius muscle weights did not change as a function of ORX. We also measured serum testosterone levels to confirm orchiectomy and androgen deprivation in ORX mice and, as expected, testosterone concentrations were significantly lower in ORX mice (10.96 Ϯ 0.63 ng/dl) compared with those in SHAM mice (723.98 Ϯ 239.16 ng/dl, P Ͻ 0.001), with residual amounts in the ORX mice likely due to secretion by the adrenal gland.
ActRIIB-mFc prevents obese phenotype in ORX mice
ActRIIB-mFc also altered fat mass. As determined by NMR, mean total fat mass in ORX controls tripled over the course of the study ( Fig. 2A) with the ORX mice ending up with 40% more of total fat (7.1 Ϯ 0.53 g) than the SHAM mice (5.0 Ϯ 0.48 g, P Ͻ 0.001). ActRIIB-mFc treatment in ORX mice significantly reduced this accumulation by more than 60% (P Ͻ 0.001) at the end of treatment, effectively maintaining mean fat mass under ORX conditions to levels (4.6 Ϯ 0.28 g) that were not significantly different (P ϭ 0.1) from SHAM controls (5.0 Ϯ 0.48 g) at study completion (Table 1 and Fig. 2A ). In addition, ActRIIB-mFc reduced the gain in mean fat mass observed in SHAM mice by end of study at d 71, 5.0 Ϯ 0.48 g vs. 3.5 Ϯ 0.19 g, respectively; however, this reduction did not reach significance (P ϭ 0.09). The effects of both ORX and ActRIIB-mFc were analogous whether expressed as total fat mass or as percentage of the total body mass ( Table 1) . As shown by micro-CT imaging (Fig. 2B) , the abdominal fat content in ORX mice treated with ActRIIB-mFc was similar to that in SHAM controls. Consistent with these results, a histological analysis of fat depots indicated that ActRIIB-mFc reduced adipocyte size in sc and epididymal depots (Fig. 2C ).
ActRIIB-mFc treatment alters circulating adipokine levels and prevents liver steatosis
ActRIIB-mFc treatment significantly reduced mean serum leptin concentrations (Fig. 3A) in SHAM (6.38 Ϯ 0.71 ng/ml, P Ͻ 0.02), but not ORX (15.16 Ϯ 1.35 ng/ml, P ϭ 0.36) mice compared with their vehicle-treated counterparts (13.38 Ϯ 2.01 ng/ml and 18.56 Ϯ 1.07 ng/ml, respectively). Mean leptin concentrations were higher in ORX mice than their SHAM counterparts but did not reach statistical significance (P ϭ 0.06). Consistent with previous findings that gonadectomy increases serum adiponectin levels in mice, mean adiponectin concentrations (Fig. 3B) were significantly higher (P Ͻ 0.0001) under ORX (126.29 Ϯ 5.78 pg/ml) conditions than SHAM conditions (47.12 Ϯ 1.74 pg/ml). ActRIIB-mFc treatment significantly increased mean serum adiponectin concentrations in both ORX (203.99 Ϯ 19.26 pg/ml) and SHAM (80.62 Ϯ 4.68 pg/ml) mice compared with the vehicletreated groups (126.29 Ϯ 5.78 pg/ml and 47.12 Ϯ 1.74 pg/ml, respectively); however, only the effects in ORX mice reached statistical significance (P Ͻ 0.0001). The adiponectin concentrations in this study represent the sum of known oligomeric isoforms (total adiponectin). ActRIIB-mFc treatment also significantly reduced mean circulating insulin concentrations (Fig. 3C ) under fed conditions compared with SHAM controls (0.77 Ϯ 0.17 ng/ml vs. 2.20 Ϯ 0.34 ng/ml, P Ͻ 0.005) but not ORX controls (0.79 Ϯ 0.15 ng/ml vs. 1.2 Ϯ 0.26 ng/ml, P ϭ 0.07). Finally, liver triglyceride content visualized by Oil Red O was increased in ORX mice compared with SHAM mice (Fig. 3D) , consistent with liver steatosis (i.e. fatty liver). This lipid-accumulating effect of ORX was prevented in ORX mice treated with ActRIIB-mFc as seen by fewer Oil Red O stained lipid droplets.
ActRIIB-mFc prevents bone loss in ORX mice
ActRIIB-mFc altered multiple indices of bone quantity and quality. As determined by whole-body analysis with DEXA, ActRIIB-mFc treatment increased bone mineral density under ORX conditions (from 0.04503 Ϯ 0. 71 (Fig. 4A ). As shown in Fig. 4 , B-F, micro-CT analysis of trabecular bone in the proximal tibia at study termination (d 71) revealed that ActRIIB-mFc treatment maintained several bone parameters in ORX mice at levels observed in SHAM controls. With respect to ORX controls, these changes included: 1) a tripling of the mean bone volume fraction from 0.0758 Ϯ 0.0096 to 0.3044 Ϯ 0.0190 (P Ͻ 0.0001; Fig. 4B ), 2) a doubling of mean number of trabeculae per millimeter from 1.9138 Ϯ 0.0952 to 4.2188 Ϯ 0.0992 (P Ͻ 0.0001; Fig. 4C ), 3) increased mean trabecular thickness from 0.0714 Ϯ 0.0030 m to 0.0923 Ϯ 0.0032 m (P Ͻ 0.01; Fig. 4D ), and 4) reduced mean trabecular separation from 0.5973 Ϯ 0.0228 m to 0.2357 Ϯ 0.0070 m (P Ͻ 0.0001; Fig. 4E ). The similarity of tibial morphology in ORX mice treated with ActRIIBmFc to that in SHAM controls is evident from representative images shown in Fig. 4F . For each of the foregoing tibia-based end points, ActRIIB-mFc treatment also produced changes in SHAM mice comparable in trend and magnitude to those in ORX mice (Fig. 4, B-F) . In addition to improving the trabecular bone parameters, ActRIIBmFc also improved cortical bone quality of tibias (Fig. 5) . ORX mice had significantly lower cortical density (1066.1 Ϯ 5.7 mg HA/ccm vs. 1089 Ϯ 6.8 mg HA/ccm, P Ͻ 0.05), but not thickness (0.215 Ϯ 0.004 mm vs. 0.235 Ϯ 0.005 mm, P ϭ 0.06), endosteal circumference (2.21 Ϯ 0.05 mm vs. 2.22 Ϯ 0.05 mm, P ϭ 0.10), and periosteal circumference (3.91 Ϯ 0.07 mm vs. 4.09 Ϯ 0.07 mm, P ϭ 0.18), than the SHAM controls (Fig. 5) . ActRIIB-mFc significantly increased cortical thickness (P Ͻ 0.002), cortical density (P Ͻ 0.01), and periosteal circumference (P Ͻ 0.05) but not endosteal circumference (P ϭ 0.71) in ORX mice (Fig.  5, A , B, D, and C, respectively). Endosteal circumference was not significantly different between any two experimental groups, even though it was trending toward lower values as a function of ActRIIB-mFc treatment in both SHAM and ORX mice (Fig. 5C) . Changes in the qualitative properties of cortical bones as a function of ORX and ActRIIB-mFc treatment are also evident in the representative CT images in Fig. 5E .
Discussion
In the current study we investigated the effects of a soluble activin type IIB receptor (ActRIIB-mFc) on multiple adverse effects of androgen deprivation in mice. The only intervention that has been shown to reverse all of the effects of castration is a direct testosterone or dihydroxytestosterone (DHT) supplementation. However, our study demonstrated that ActRIIB-mFc completely prevented muscle mass loss (Fig. 1 ), fat accumulation (Fig. 2) , and bone loss (Figs. 4 and 5 ) in castrated mice. The ability of ActRIIB-mFc treatment to overcome the attenuating effects of orchiectomy on body mass, lean mass, and the specific muscles examined (pectoralis, femoris and gastrocnemius) is consistent with its physico- chemical properties. This soluble form of the activin type IIB receptor competes with the natural receptor for ligands which include myostatin (GDF-8), a negative regulator of muscle development. Myostatin overexpression results in a decrease in muscle mass in both human (17, 18) and animal (19 -21) models, whereas myostatin deficiency results in an enhanced muscular phenotype (22) (23) (24) (25) (26) . Myostatin signaling occurs via binding with high-affinity to ActRIIB. However, inhibition of ActRIIB signaling produces a greater increase in skeletal muscle than selective inhibition of myostatin alone (9) , indicating that ActRIIB mediates both myostatin-dependent and independent regulation of lean tissue mass and could therefore provide a broader-based therapeutic target in the treatment of the muscle-wasting side-effect of androgen depletion strategies such as orchiectomy.
Concerning fat regulation, microarray analysis has shown that adipose tissue expresses activin type I and type II receptors (27) . In addition to inhibiting myogenesis in mesenchymal multipotent cells, GDF-8 also stimulated expression of early and late markers of adipogenesis (28) . While GDF-8 has been shown to promote adipogenesis (13, 25) , its role in mature adipocyte function is less clear. Mice lacking myostatin gene have less body fat and are resistant to diet-induced obesity (13) . Inhibition of myostatin in muscle alone but not fat resulted in decreased fat mass and improved insulin sensitivity (29) . Furthermore, a soluble ActRIIB administration reduced body fat in mice fed both regular chow and high-fat diets and resulted in improved insulin sensitivity (30) . These current findings suggest that the effects of systemic ActRIIB signaling inhibition on body fat might be predominantly due to the secondary effects of growing muscle tissue on fat storages.
In addition to investigating the effects of ActRIIB-mFc on fat accumulation, we also demonstrated that ActRIIBmFc promoted a preferred adipokine expression profile accompanied by lower fed insulin levels and prevented liver steatosis in castrated mice (Fig. 3) . There is agreement that adiponectin levels generally vary inversely with fat mass and that adiponectin is an insulin-sensitizing adipokine with antidiabetic, antiatherogenic, and cardioprotective properties (31) . In the present experiment, adiponectin concentrations were higher under ORX conditions than SHAM conditions, as expected from the known inhibitory effect of testosterone on adiponectin in mice (32) . This has been suggested as the reason for obese ORX mice being less likely to develop insulin resistance than dietinduced obese mice. Also, leptin concentrations were higher in ORX mice than their sham counterparts, consistent with increased adiposity and the known inhibitory effect of testosterone on leptin (33) .
ActRIIB has been implicated in the binding of a very diverse group of TGF-␤ family members in addition to myostatin (GDF-8) that regulate bone growth. These include activin A, bone morphogenetic protein (BMP)-7, and BMP-2 (34 -37). In the current study we have demonstrated the ability of ActRIIB-mFc treatment to overcome the attenuating effects of orchiectomy on bone quality. It has been suggested that GDF-8 and GDF-11 are derived from one ancestral gene (38) . Even though GDF-8 and GDF-11 are highly related members of the TGF-␤ family of proteins, until recently it was believed that they have very different functions, with GDF-8 being involved only in muscle tissue maintenance and GDF-11 in formation and maintenance of axial skeleton. However, recent findings suggest that GDF-8 and GDF-11 have redundant functions in regulation of skeletal development (12) . This study provides evidence for one potential mechanism explaining the effects of ActRIIB-mFc on bone in ORX and SHAM mice seen in our study. Furthermore, activin A is one of the most abundant proteins of the TGF-␤/BMP family found in bone, and it has been proposed to be a negative regulator of bone formation. Activin A has a high affinity for both ActRIIA and ActRIIB. It has been demonstrated that treatment with a soluble derivative of ActRIIA leads to increased bone formation, bone mass, and bone strength both in gonad-intact mice and in ovariectomized mice with established bone loss (39) . In addition, it was recently reported that soluble ActRIIA-mFc improved bone mass as well as structure in female cynomologus macaques (40) due to both anabolic as well as antiresorptive mechanisms (41) . We anticipate that the mechanism of the bone effects reported here with ActRIIB-mFc is due to blocking the same ligand/s as activins as with ActRIIA-mFc (37) and is therefore analogous to the anabolic mechanism responsible for the bone building effects reported with ActRIIA-mFc.
These results demonstrate that treatment with ActRIIBmFc can alleviate detrimental effects of androgen deprivation on body composition in males. Under androgendeprived conditions, ActRIIB-mFc reduced adiposity and increased bone quality, lean body mass, and muscle mass. For most end points examined, treatment with ActRIIBmFc completely prevented detrimental changes associated with androgen deprivation, restoring levels at least to those in SHAM controls. In turn, treatment effects under SHAM conditions were generally comparable in direction and magnitude to those observed under androgendeprived conditions. Effects of ActRIIB-mFc on body composition were accompanied by significantly elevated concentrations of circulating adiponectin, an important insulin-sensitizing adipokine with antidiabetic, antiatherogenic, and cardioprotective properties. Furthermore, these elevated serum adiponectin levels were correlated with lower insulin levels and lower liver triglyceride content. Taken together, these findings indicate that inhibition of ActRIIB signaling represents a promising adjunct therapeutic paradigm for men receiving androgen deprivation therapy for advanced or high-risk forms of prostate and other types of androgen-dependent cancers. Therefore, it is plausible that the comprehensive improvements in body composition, metabolic parameters, and bone health resulting from ActRIIB-mFc would further increase life quality as well as life expectancy of these patients. The current study investigated preventative effects of ActRIIB signaling inhibition in growing mice that were surgically androgen deprived from young age; therefore, future studies should investigate therapeutic potential of ActRIIB signaling inhibition in adult mice undergoing chemical androgen deprivation therapies, such as androgen antagonist (bicalutamide and flutamide) or gonadotropin-releasing hormone (GnRH) analog therapies.
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